Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The payments have raised concerns that doctors could be influenced to favour specific drugs or prescribe them over talking ...

Trans-Tasman drug developer Aft Pharmaceuticals is targeting lucrative niche diseases its Big Pharma rivals have ignored ...

Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from ...

Tariffs on pharmaceutical imports could hurt Lilly, especially with its dependence on products made in Ireland. The president ...

The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids ...

The U.S. is proposing major policy changes to its healthcare sector, including imposing tariffs on global manufacturers. Click to read.

Joining with Democratic U.S. Sen. Jeanne Shaheen of New Hampshire, Missouri’s senior GOP senator wants to end federal subsidies for drug company advertising.

A February executive order on pharmaceutical price transparency does nothing to change the incentives that keep costs opaque. But drug companies and other stakeholders would reap the benefits of such ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

HHS Secretary Robert F. Kennedy Jr. is escalating his war on institutions he says are influenced by pharmaceutical companies.

Barclays analysts downgraded CoreWeave (CRWV) to Equal Weight, raising valuation concerns. This is CoreWeave's first ...